Nadolska Krystyna, Goś Roman
Z Kliniki Okulistyki i Rehabilitacji Wzrokowej Uniwersytetu Medycznego, Łodzi.
Klin Oczna. 2008;110(7-9):314-7.
Over a period of several decades numerous scientific research has proven that, regardless of the route of administration, cannabinoids are able to decrease intraocular pressure. What is more, these compounds are characterized by neuroprotection and vasodilatation properties, that additionally substantiate it's therapeutic utility in conservative treatment of glaucoma. So far, it has not been described in details what mechanism is used to lower the intraocular pressure by cannabinoids. Nevertheless, the presence of endocannabinoid receptors in structures of the eye responsible for formation and outflow of aqueous humor is an explanation for effectiveness of these compounds, when administered in topical form. These days, with the aid of modern pharmacological technology are available significantly bigger possibilities of improving bioavailability of cannabinoids administered to the eye than in the past, as well as limitation of it's undesired side effects.
在几十年的时间里，大量科学研究证明，无论给药途径如何，大麻素都能够降低眼压。此外，这些化合物具有神经保护和血管舒张特性，这进一步证实了其在青光眼保守治疗中的治疗效用。到目前为止，尚未详细描述大麻素降低眼压所使用的机制。然而，眼内负责房水生成和流出的结构中存在内源性大麻素受体，这解释了这些化合物以局部形式给药时的有效性。如今，借助现代药理学技术，与过去相比，提高眼部给药大麻素的生物利用度以及限制其不良副作用的可能性显著增加。
